New & Noteworthy

September 2023

New Drug Application Approval

Innoviva, Inc

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc, announces the US FDA approval of Xacduro (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

Request More Information

Current Issue